SAREUM HOLDINGS PLC

Regulatory Filings • Jun 30, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9237K

Sareum Holdings PLC

30 June 2014

(AIM : SAR)	30 June 2014

Sareum Holdings plc

("Sareum" or "the Company")

Total Voting Rights

The Company announces that, pursuant to the requirements of the Disclosure and Transparency Rules, the total number of voting rights in respect of each class of share in issue and admitted to trading on AIM at the date of this announcement is as follows:

	Total number of shares in issue	Total number of voting rights
Ordinary Shares of 0.025 pence each	1,910,038,273	1,910,038,273

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

For further information:
Sareum Holdings plc Tim Mitchell	01223 497 700
Sanlam Securities UK Limited (Nomad) Simon Clements / James Thomas	020 7628 2200
Hybridan LLP (Broker) Claire Noyce / William Lynne	0203 713 4581/ 4582
The Communications Portfolio Limited (Media enquiries) Ariane Comstive [email protected]	020 7536 2028

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers.  Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVRWGURUQUPCGWU